Carla M Mamolo (Carla Mamolo, C Mamolo)

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 9

Top Topics

Chronic Myeloid Leukemia

Muscle Invasive Bladder Cancer

Top Venues

Future oncology (London, England)

Current medical research and opinion

BMC dermatology

Applied health economics and health policy

This page only lists publications with an associated author ORCID identifier.

Publications

Matthew Lyall, Rebecca Crawford, Timothy Bell, Carla M Mamolo, Alexander Neuhof, Courtney Levy, Anne Heyes
Characterizing the Patient Journey in Multiple Myeloma: Qualitative Review. JMIR cancer 8 (3) (2022)
T Alexander Russell-Smith, Laura Gurskyte, Bogdan Muresan, Carla M Mamolo, Ana Gezin, Joseph C Cappelleri, Bart Heeg
Efficacy of non-intensive therapies approved for relapsed/refractory acute myeloid leukemia: a systematic literature review. Future oncology (London, England) 18 (16) (2022)
Bogdan Muresan, Carla M Mamolo, Joseph C Cappelleri, Ruth Mokgokong, Athina Palaka, Fanni Soikkeli, Bart Heeg
Comparing cure rates for gemtuzumab ozogamicin plus standard chemotherapy vs standard chemotherapy alone in acute myeloid leukemia patients. Future oncology (London, England) 17 (22) (2021)
Bogdan Muresan, Carla M Mamolo, Joseph C Cappelleri, Eric Leip, Andrea Viqueira, Bart Heeg
An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia. Current medical research and opinion 37 (5) (2021)
B Muresan, Carla M Mamolo, J C Cappelleri, M J Postma, B Heeg
Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting. Applied health economics and health policy 19 (6) (2021)
Lauren J Lee, Christina S Kwon, Anna Forsythe, Carla M Mamolo, Elizabeth T Masters, Ira A Jacobs
Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature Reviews. ClinicoEconomics and outcomes research : CEOR 12 (2020)
Carla M Mamolo, Verna Welch, Roland B Walter, Joseph C Cappelleri, James Brockbank, Matthew Cawson, Chris Knight, Michele Wilson
Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia. PharmacoEconomics 39 (1) (2020)
Jorge E Cortes, Bogdan Muresan, Carla M Mamolo, Joseph C Cappelleri, Rocco J Crescenzo, Yun Su, Carlo Gambacorti-Passerini, Bart Heeg, B Douglas Smith
Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia. Current medical research and opinion 35 (9) (2019)
Kristina Callis Duffin, Andrew G Bushmakin, Joseph C Cappelleri, Lotus Mallbris, Carla M Mamolo
A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies. BMC dermatology 19 (1) (2019)